---
layout: default
title: Paclitaxel
description: "Paclitaxel çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 122
evidence_level: L1
indication_count: 10
---

# Paclitaxel

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Paclitaxel è—¥å¸«ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Paclitaxel å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Paclitaxel ç‚ºç´«æ‰é†‡é¡æŠ—è…«ç˜¤è—¥ç‰©ï¼ŒTxGNN é æ¸¬å…¶å°ä¹³ç™Œ (åŒ…æ‹¬ä¸‰é™°æ€§ä¹³ç™Œã€é›Œæ¿€ç´ å—é«”é™½æ€§ä¹³ç™Œ) æœ‰æ²»ç™‚æ½›åŠ›ï¼Œæ­¤é æ¸¬å·²ç²å¤§é‡ Phase III è‡¨åºŠè©¦é©—è­‰å¯¦ï¼Œè­‰æ“šç­‰ç´šæœ€é«˜ã€‚
</p>


---

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥å“åç¨± | Paclitaxel (ç´«æ‰é†‡) |
| DrugBank ID | DB01229 |
| å°ç£å•†å“å | æ›²æ–¯è‹¥å‡æ™¶æ³¨å°„åŠ‘ã€æ±°ç™Œå‹æ³¨å°„åŠ‘ç­‰ |
| åŸé©æ‡‰ç—‡ | åµå·¢ç™Œã€ä¹³ç™Œã€éå°ç´°èƒè‚ºç™Œã€èƒƒç™Œã€é£Ÿé“ç™Œã€é ­é ¸ç™Œã€è†€èƒ±ç™Œã€å­å®®é ¸ç™Œ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | å¥³æ€§ä¹³è…ºç™Œã€hereditary breast ovarian cancer syndromeã€estrogen-receptor negative breast cancerã€hormone-resistant breast carcinomaã€estrogen-receptor positive breast cancerã€Ehrlich tumor carcinomaã€bilateral breast carcinomaã€breast carcinoma by gene expression profileã€nipple carcinomaã€ovarian clear cell adenocarcinoma |
| è­‰æ“šç­‰ç´š | L1 (å¤šå€‹ RCT) |
| TxGNN é æ¸¬åˆ†æ•¸ | 0.999+ |

---



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. female breast carcinoma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">100.00%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>### æ©Ÿè½‰é€£çµ</p>

<ol>
<li><strong>å¾®ç®¡ç©©å®šä½œç”¨</strong>ï¼šPaclitaxel çµåˆ beta-tubulin ä¿ƒé€²å¾®ç®¡èšåˆä¸¦ç©©å®šå¾®ç®¡ï¼ŒæŠ‘åˆ¶æœ‰çµ²åˆ†è£‚ï¼Œå°è‡´ç´°èƒå‡‹äº¡ã€‚</li>

<li><strong>å…ç–«èª¿ç¯€ä½œç”¨</strong>ï¼šæœ€æ–°ç ”ç©¶é¡¯ç¤º paclitaxel å¯èª¿ç¯€è…«ç˜¤ç›¸é—œå·¨å™¬ç´°èƒ (TAM)ï¼Œå¢å¼· PD-1 é˜»æ–·åŠ‘çš„ç™‚æ•ˆã€‚</li>

<li><strong>å…‹æœè·çˆ¾è’™æŠ—æ€§</strong>ï¼šå°æ–¼è·çˆ¾è’™æ²»ç™‚ç„¡æ•ˆçš„ ER+ ä¹³ç™Œï¼ŒåŒ–ç™‚ä»æ˜¯é‡è¦é¸é …ï¼Œpaclitaxel é€éä¸ä¾è³´è·çˆ¾è’™å—é«”çš„æ©Ÿåˆ¶ç™¼æ®ä½œç”¨ã€‚</li>
</ol>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>### å·²å®Œæˆçš„ Phase III è©¦é©—</p>

<table>
<thead>
<tr>
<th>è©¦é©—ç·¨è™Ÿ</th>
<th>ç–¾ç—…</th>
<th>ç™‚æ³•</th>
<th>ç‹€æ…‹</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT00281658</td>
<td>ErbB2 é™½æ€§è½‰ç§»æ€§ä¹³ç™Œ</td>
<td>Lapatinib + Paclitaxel vs Paclitaxel</td>
<td>å®Œæˆ</td>
<td>è©•ä¼°æ•´é«”å­˜æ´»æœŸ</td>
</tr>
<tr>
<td>NCT01583426</td>
<td>æ—©æœŸä¹³ç™Œ</td>
<td>Nab-paclitaxel vs å‚³çµ± Paclitaxel</td>
<td>å®Œæˆ</td>
<td>æ¯”è¼ƒç—…ç†å®Œå…¨åæ‡‰ç‡</td>
</tr>
<tr>
<td>NCT03725059</td>
<td>ER+/HER2- ä¹³ç™Œ</td>
<td>Pembrolizumab + åŒ–ç™‚ (å« Paclitaxel)</td>
<td>æ‹›å‹Ÿä¸­</td>
<td>è©•ä¼° pCR åŠ EFS</td>
</tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»</h3>

<p>### ä¸‰é™°æ€§ä¹³ç™Œ (TNBC)</p>

<table>
<thead>
<tr>
<th>PMID</th>
<th>ç™¼è¡¨å¹´ä»½</th>
<th>ç ”ç©¶é¡å‹</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td>31783552</td>
<td>2019</td>
<td>ç¶œè¿°</td>
<td>Paclitaxel æ˜¯ TNBC ç¬¬ä¸€ç·šæ²»ç™‚è—¥ç‰©ï¼Œnab-PTX å¯æé«˜ç™‚æ•ˆä¸¦é™ä½å‰¯ä½œç”¨</td>
</tr>
<tr>
<td>39009452</td>
<td>2024</td>
<td>åŸºç¤ç ”ç©¶</td>
<td>Paclitaxel é€é TLR4 èª¿ç¯€ TAMï¼Œå¢å¼· PD-1 é˜»æ–·åŠ‘ç™‚æ•ˆ</td>
</tr>
<tr>
<td>35795050</td>
<td>2022</td>
<td>ç¶œè¿°</td>
<td>TNBC å…ç–«ç™‚æ³•é€²å±•ï¼ŒPembrolizumab + åŒ–ç™‚å·²æˆç‚ºæ¨™æº–æ²»ç™‚</td>
</tr>
<tr>
<td>35976445</td>
<td>2023</td>
<td>ç¶œè¿°</td>
<td>ä¸‰é™°æ€§ä¹³ç™Œæ ¸å‡†æ²»ç™‚é¸é …åŠå…¶ä½œç”¨æ©Ÿè½‰</td>
</tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. estrogen-receptor negative breast cancer</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ50 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01777932" target="_blank">NCT01777932</a></td><td>N/A</td><td>COMPLETED</td><td>220</td><td>A Multicenter, Single-arm, Observational Study Describing the Clinical Benefits ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04132817" target="_blank">NCT04132817</a></td><td>PHASE1</td><td>COMPLETED</td><td>12</td><td>A Phase 1 Multi-Targeted Study to Promote Anti-Tumor Immunity in ER Positive, HE...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02734290" target="_blank">NCT02734290</a></td><td>PHASE1, PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>29</td><td>A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pe...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04152057" target="_blank">NCT04152057</a></td><td>PHASE1, PHASE2</td><td>UNKNOWN</td><td>20</td><td>A Single-arm, Exploratory Clinical Study of Pyrotinib Maleate Tablets Combined W...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01897441" target="_blank">NCT01897441</a></td><td>NA</td><td>TERMINATED</td><td>31</td><td>Prospective Tissue Collection in Breast Cancer Patients Receiving Preoperative S...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 45 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38771995/" target="_blank">38771995</a></td><td>2024</td><td>Article</td><td>Journal of clinical </td><td>Final Results of RIGHT Choice: Ribociclib Plus Endocrine The...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33015734/" target="_blank">33015734</a></td><td>2021</td><td>Article</td><td>Cancer immunology, i</td><td>Pembrolizumab and atezolizumab in triple-negative breast can...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37440239/" target="_blank">37440239</a></td><td>2023</td><td>Article</td><td>JAMA oncology</td><td>Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37526149/" target="_blank">37526149</a></td><td>2023</td><td>Article</td><td>Future oncology (Lon</td><td>TROPION-Breast02: Datopotamab deruxtecan for locally recurre...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39838117/" target="_blank">39838117</a></td><td>2025</td><td>Article</td><td>Nature medicine</td><td>Pembrolizumab and chemotherapy in high-risk, early-stage, ER...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. hormone-resistant breast carcinoma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ14 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03285607" target="_blank">NCT03285607</a></td><td>PHASE1</td><td>WITHDRAWN</td><td>0</td><td>Phase I Study of MCS110 Combined With Neoadjuvant Dose-Dense Doxorubicin, Cyclop...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02616848" target="_blank">NCT02616848</a></td><td>PHASE1</td><td>UNKNOWN</td><td>1</td><td>Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-neg...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04771871" target="_blank">NCT04771871</a></td><td>PHASE2</td><td>UNKNOWN</td><td>42</td><td>Treatment Response and microRNA Profiles in Triple Negative Breast Cancer Patien...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02603679" target="_blank">NCT02603679</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>181</td><td>PREDIX Luminal B - Neoadjuvant Response-guided Treatment of ER Positive Tumors W...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01031446" target="_blank">NCT01031446</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>55</td><td>A Phase Ib/II Study of Cisplatin, Paclitaxel, and RAD001 in Patients With Metast...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 9 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ9 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9071337/" target="_blank">9071337</a></td><td>1997</td><td>Article</td><td>Seminars in oncology</td><td>Response to estramustine phosphate and paclitaxel in patient...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8091238/" target="_blank">8091238</a></td><td>1994</td><td>Article</td><td>Seminars in oncology</td><td>Salvage chemotherapy of breast cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34781168/" target="_blank">34781168</a></td><td>2021</td><td>Article</td><td>European journal of </td><td>TAKTIC: A prospective, multicentre, uncontrolled, phase IB/I...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/7481851/" target="_blank">7481851</a></td><td>1995</td><td>Article</td><td>Seminars in oncology</td><td>Management of breast cancer: status and future trends.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9374083/" target="_blank">9374083</a></td><td>1997</td><td>Article</td><td>Seminars in oncology</td><td>Chemotherapy of breast cancer: a historical perspective.</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 4 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. estrogen-receptor positive breast cancer</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ50 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01777932" target="_blank">NCT01777932</a></td><td>N/A</td><td>COMPLETED</td><td>220</td><td>A Multicenter, Single-arm, Observational Study Describing the Clinical Benefits ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06202261" target="_blank">NCT06202261</a></td><td>PHASE1, PHASE2</td><td>RECRUITING</td><td>154</td><td>A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of TQB2930 for ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04132817" target="_blank">NCT04132817</a></td><td>PHASE1</td><td>COMPLETED</td><td>12</td><td>A Phase 1 Multi-Targeted Study to Promote Anti-Tumor Immunity in ER Positive, HE...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04152057" target="_blank">NCT04152057</a></td><td>PHASE1, PHASE2</td><td>UNKNOWN</td><td>20</td><td>A Single-arm, Exploratory Clinical Study of Pyrotinib Maleate Tablets Combined W...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01897441" target="_blank">NCT01897441</a></td><td>NA</td><td>TERMINATED</td><td>31</td><td>Prospective Tissue Collection in Breast Cancer Patients Receiving Preoperative S...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 45 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38771995/" target="_blank">38771995</a></td><td>2024</td><td>Article</td><td>Journal of clinical </td><td>Final Results of RIGHT Choice: Ribociclib Plus Endocrine The...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37440239/" target="_blank">37440239</a></td><td>2023</td><td>Article</td><td>JAMA oncology</td><td>Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30413379/" target="_blank">30413379</a></td><td>2018</td><td>Article</td><td>The Lancet. Oncology</td><td>Neoadjuvant chemotherapy with or without anthracyclines in t...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39838117/" target="_blank">39838117</a></td><td>2025</td><td>Article</td><td>Nature medicine</td><td>Pembrolizumab and chemotherapy in high-risk, early-stage, ER...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39631485/" target="_blank">39631485</a></td><td>2024</td><td>Article</td><td>Pharmacological rese</td><td>Targeted and cytotoxic inhibitors used in the treatment of b...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. Ehrlich tumor carcinoma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ1 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04885270" target="_blank">NCT04885270</a></td><td>PHASE3</td><td>UNKNOWN</td><td>50</td><td>Phase III Clinical Trial of Intravenous Paclitaxel Plus Intraperitoneal Cisplati...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30342146/" target="_blank">30342146</a></td><td>2019</td><td>Article</td><td>International journa</td><td>Acylated chitosan anchored paclitaxel loaded liposomes: Phar...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31002367/" target="_blank">31002367</a></td><td>2019</td><td>Article</td><td>Oncology reports</td><td>Dietary baker&#x27;s yeast sensitizes Ehrlich mammary adenocarcin...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27426109/" target="_blank">27426109</a></td><td>2016</td><td>Article</td><td>International journa</td><td>Heparin modification enhances the delivery and tumor targeti...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26500095/" target="_blank">26500095</a></td><td>2016</td><td>Article</td><td>Tumour biology : the</td><td>The combination of thymoquinone and paclitaxel shows anti-tu...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17385543/" target="_blank">17385543</a></td><td>2007</td><td>Article</td><td>Acta biologica Hunga</td><td>Evaluation of the effect of paclitaxel, epirubicin and tamox...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. bilateral breast carcinoma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ5 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02364726" target="_blank">NCT02364726</a></td><td>NA</td><td>COMPLETED</td><td>28</td><td>Acupuncture to Reduce Chemotherapy-induced Peripheral Neuropathy Severity During...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04461977" target="_blank">NCT04461977</a></td><td>NA</td><td>COMPLETED</td><td>60</td><td>Acupuncture for Treatment of Peripheral Neuropathy Induced by Neoadjuvant or Adj...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02457039" target="_blank">NCT02457039</a></td><td>NA</td><td>COMPLETED</td><td>93</td><td>An Assessor-Blinded, Randomised Controlled Trial of Acupuncture to Prevent Chemo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03873272" target="_blank">NCT03873272</a></td><td>NA</td><td>COMPLETED</td><td>63</td><td>Randomized Controlled Selection Trial of Cryotherapy vs. Compression Therapy for...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05861830" target="_blank">NCT05861830</a></td><td>PHASE3</td><td>RECRUITING</td><td>80</td><td>An Exploratory Study on Predicting the Efficacy of Dalpiciclib in Combination Wi...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40690248/" target="_blank">40690248</a></td><td>2025</td><td>Article</td><td>JAMA</td><td>Ovarian Cancer: A Review.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36068624/" target="_blank">36068624</a></td><td>2022</td><td>Article</td><td>International journa</td><td>Bilateral intermediate uveitis following treatment with pacl...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36335424/" target="_blank">36335424</a></td><td>2022</td><td>Article</td><td>The American journal</td><td>Gynecomastia and Malignancy: A Case of Male Invasive Ductal ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25978147/" target="_blank">25978147</a></td><td>2017</td><td>Article</td><td>Journal of chemother</td><td>Paclitaxel-induced pneumonitis in patients with breast cance...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11876386/" target="_blank">11876386</a></td><td>2002</td><td>Article</td><td>European journal of </td><td>Primary breast carcinoma of the vulva: case report and revie...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. breast carcinoma by gene expression profile</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ45 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02628132" target="_blank">NCT02628132</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>22</td><td>Study of the Safety, Tolerability and Efficacy of the Investigational Anti PD-L1...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00589238" target="_blank">NCT00589238</a></td><td>PHASE2</td><td>TERMINATED</td><td>16</td><td>Randomised Phase II Trial of Neoadjuvant Weekly Paclitaxel Plus Carboplatin Comp...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03725436" target="_blank">NCT03725436</a></td><td>PHASE1</td><td>ACTIVE_NOT_RECRUITING</td><td>35</td><td>A Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 A...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01722968" target="_blank">NCT01722968</a></td><td>PHASE2</td><td>COMPLETED</td><td>33</td><td>A Prospective Randomized Phase II Study to Identify Predictive Biomarkers and Me...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00499291" target="_blank">NCT00499291</a></td><td>NA</td><td>WITHDRAWN</td><td>0</td><td>Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Study of Nab-Paclitaxel (Na...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 40 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26372358/" target="_blank">26372358</a></td><td>2016</td><td>Article</td><td>Molecular oncology</td><td>Genomic signatures for paclitaxel and gemcitabine resistance...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39400682/" target="_blank">39400682</a></td><td>2024</td><td>Article</td><td>Medical oncology (No</td><td>Glycolytic pathway analysis and gene expression profiles of ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30426838/" target="_blank">30426838</a></td><td>2018</td><td>Article</td><td>Molecular pain</td><td>Expression of mitochondrial dysfunction-related genes and pa...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36602784/" target="_blank">36602784</a></td><td>2023</td><td>Article</td><td>JAMA oncology</td><td>Prognostic and Predictive Value of Immune-Related Gene Expre...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27094684/" target="_blank">27094684</a></td><td>2016</td><td>Article</td><td>Scientific reports</td><td>Genome-wide profiles of methylation, microRNAs, and gene exp...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. nipple carcinoma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ2 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03875573" target="_blank">NCT03875573</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>147</td><td>Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Pr...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00616967" target="_blank">NCT00616967</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>68</td><td>A Multi-Institutional Double-Blind Phase II Study Evaluating Response and Surrog...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ10 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39233823/" target="_blank">39233823</a></td><td>2024</td><td>Article</td><td>Oncology letters</td><td>Neoadjuvant chemotherapy for primary invasive ductal carcino...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33827325/" target="_blank">33827325</a></td><td>2021</td><td>Article</td><td>International journa</td><td>Acinic Cell Carcinoma of the Breast: Report of a Case With I...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37064212/" target="_blank">37064212</a></td><td>2023</td><td>Article</td><td>Case reports in wome</td><td>Ovarian high-grade serous carcinoma with estrogenic manifest...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29514832/" target="_blank">29514832</a></td><td>2018</td><td>Article</td><td>BMJ case reports</td><td>Rare case of metaplastic breast cancer in a man.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38741768/" target="_blank">38741768</a></td><td>2024</td><td>Article</td><td>Frontiers in medicin</td><td>Untypical bilateral breast cancer with peritoneal fibrosis o...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 5 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. parameningeal embryonal rhabdomyosarcoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.73%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. botryoid-type embryonal rhabdomyosarcoma of the vagina</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.73%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

Paclitaxel åœ¨å°ç£æœ‰å¤šç¨®è£½åŠ‘æ ¸å‡†ä¸Šå¸‚ï¼ŒåŒ…æ‹¬ï¼š

- å‚³çµ±æº¶åŠ‘å‹ Paclitaxel æ³¨å°„åŠ‘
- Nab-paclitaxel (ç™½è›‹ç™½çµåˆå‹)
- Paclitaxel å¾®è„‚ç²’æ³¨å°„åŠ‘

åŸé©æ‡‰ç—‡å·²æ¶µè“‹ä¹³ç™Œçš„å¤šç¨®é¡å‹ã€‚

---

## å®‰å…¨æ€§è€ƒé‡

### é‡è¦è­¦èª

- **éæ•åæ‡‰**ï¼šå‚³çµ±è£½åŠ‘å« Cremophor ELï¼Œå¯èƒ½å°è‡´åš´é‡éæ•åæ‡‰ï¼Œéœ€é é˜²çµ¦è—¥
- **éª¨é«“æŠ‘åˆ¶**ï¼šå—œä¸­æ€§çƒä½ä¸‹ç‚ºåŠ‘é‡é™åˆ¶æ¯’æ€§
- **å‘¨é‚Šç¥ç¶“ç—…è®Š**ï¼šç´¯ç©åŠ‘é‡ç›¸é—œï¼Œå¯èƒ½ä¸å¯é€†
- **å¿ƒè‡Ÿæ¯’æ€§**ï¼šèˆ‡ anthracycline ä½µç”¨æ™‚éœ€æ³¨æ„

### å¸¸è¦‹å‰¯ä½œç”¨

| å‰¯ä½œç”¨ | ç™¼ç”Ÿç‡ |
|--------|--------|
| éª¨é«“æŠ‘åˆ¶ | éå¸¸å¸¸è¦‹ |
| å‘¨é‚Šç¥ç¶“ç—…è®Š | å¸¸è¦‹ |
| è‚Œè‚‰é—œç¯€ç—› | å¸¸è¦‹ |
| å™å¿ƒå˜”å | å¸¸è¦‹ |
| æ‰é«® | éå¸¸å¸¸è¦‹ |

### è—¥ç‰©äº¤äº’ä½œç”¨

- **CYP3A4 åŠ CYP2C8 æŠ‘åˆ¶åŠ‘**ï¼šå¯èƒ½å¢åŠ  paclitaxel è¡€ä¸­æ¿ƒåº¦
- **CYP3A4 èª˜å°åŠ‘**ï¼šå¯èƒ½é™ä½ç™‚æ•ˆ
- **Anthracyclines**ï¼šå»ºè­°å…ˆçµ¦ paclitaxel å†çµ¦ anthracycline

### ç‰¹æ®Šæ—ç¾¤

- **è‚åŠŸèƒ½ä¸å…¨**ï¼šéœ€æ ¹æ“šè†½ç´…ç´ åŠ AST èª¿æ•´åŠ‘é‡
- **å­•å©¦**ï¼šç¦å¿Œä½¿ç”¨
- **è€å¹´äºº**ï¼šå‘¨é‚Šç¥ç¶“ç—…è®Šé¢¨éšªè¼ƒé«˜

---




### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**è‘¡è„æŸšæ±** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šå½±éŸ¿è—¥ç‰©ä»£è¬ã€‚å¯èƒ½å¢åŠ è—¥ç‰©è¡€ä¸­æ¿ƒåº¦ã€‚
- å»ºè­°ï¼šéœ€ç›£æ¸¬ç™‚æ•ˆæˆ–ä¸è‰¯åæ‡‰ã€‚å¯èƒ½éœ€èª¿æ•´åŠ‘é‡ã€‚é¿å…é£Ÿç”¨è‘¡è„æŸšæˆ–è‘¡è„æŸšæ±ã€‚

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**è–ç´„ç¿°è‰ï¼ˆè²«è‘‰é€£ç¿¹ï¼‰** ğŸ”´ Major
- å½±éŸ¿ï¼šè–ç´„ç¿°è‰é™ä½åŒ–ç™‚è—¥ç‰©ç™‚æ•ˆ
- å»ºè­°ï¼šåŒ–ç™‚æœŸé–“ç¦ç”¨æ‰€æœ‰è‰è—¥è£œå……å“


## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### æ•´é«”è©•ä¼°

Paclitaxel å°ä¹³ç™Œçš„é æ¸¬å·²ç²å¾—æœ€é«˜ç­‰ç´šçš„è‡¨åºŠè­‰æ“šæ”¯æŒï¼š

1. **è­‰æ“šç­‰ç´šæœ€é«˜ (L1)**ï¼šå¤šå€‹ Phase III è‡¨åºŠè©¦é©—è­‰å¯¦ç™‚æ•ˆ
2. **æ©Ÿè½‰æ¸…æ™°**ï¼šå¾®ç®¡ç©©å®šåŠå…ç–«èª¿ç¯€é›™é‡ä½œç”¨
3. **è‡¨åºŠæ‡‰ç”¨æˆç†Ÿ**ï¼šå·²æ˜¯ä¹³ç™Œæ¨™æº–æ²»ç™‚çš„é‡è¦çµ„æˆéƒ¨åˆ†
4. **æŒçºŒå‰µæ–°**ï¼šèˆ‡å…ç–«ç™‚æ³•ä½µç”¨çš„æ–°çµ„åˆæ­£åœ¨ç ”ç©¶ä¸­

### ç›®å‰è‡¨åºŠå®šä½

| ä¹³ç™Œäºå‹ | Paclitaxel åœ¨æ²»ç™‚ä¸­çš„è§’è‰² |
|----------|---------------------------|
| ä¸‰é™°æ€§ä¹³ç™Œ | ç¬¬ä¸€ç·šåŒ–ç™‚æ ¸å¿ƒè—¥ç‰©ï¼Œå¸¸èˆ‡å…ç–«ç™‚æ³•ä½µç”¨ |
| HER2+ ä¹³ç™Œ | èˆ‡ trastuzumab ä½µç”¨çš„æ¨™æº–æ–¹æ¡ˆ |
| ER+/HER2- ä¹³ç™Œ | è·çˆ¾è’™æ²»ç™‚ç„¡æ•ˆå¾Œçš„åŒ–ç™‚é¸é … |
| ç™¼ç‚æ€§ä¹³ç™Œ | å‰å°åŒ–ç™‚çš„é‡è¦æˆåˆ† |

### å»ºè­°è¡Œå‹•

- **æŒçºŒä½œç‚ºæ¨™æº–æ²»ç™‚**ï¼šPaclitaxel åœ¨ä¹³ç™Œæ²»ç™‚ä¸­çš„åœ°ä½å·²ç¢ºç«‹
- **é—œæ³¨æ–°çµ„åˆç™‚æ³•**ï¼šèˆ‡ PD-1/PD-L1 æŠ‘åˆ¶åŠ‘çš„ä½µç”¨ç ”ç©¶
- **å€‹äººåŒ–é†«ç™‚**ï¼šæ ¹æ“šç”Ÿç‰©æ¨™è¨˜é¸æ“‡æœ€é©åˆçš„æ²»ç™‚çµ„åˆ

---

*æœ¬å ±å‘Šç”± TxGNN é æ¸¬ç³»çµ±ç”Ÿæˆï¼Œåƒ…ä¾›ç ”ç©¶åƒè€ƒï¼Œä¸æ§‹æˆé†«ç™‚å»ºè­°ã€‚*


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Benzylpenicillin]({{ "/drugs/benzylpenicillin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Allopurinol]({{ "/drugs/allopurinol/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Cerliponase Alfa]({{ "/drugs/cerliponase_alfa/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Thiamine]({{ "/drugs/thiamine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Buprenorphine]({{ "/drugs/buprenorphine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Paclitaxelè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/paclitaxel/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_paclitaxel,
  title = {Paclitaxelè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/paclitaxel/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
